Department of Biology, School of Life Sciences, Southern University of Science and Technology, Shenzhen, China.
Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong SAR, China.
Front Immunol. 2021 Dec 23;12:755844. doi: 10.3389/fimmu.2021.755844. eCollection 2021.
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by inflammation and bone erosion. The exact mechanism of RA is still unknown, but various immune cytokines, signaling pathways and effector cells are involved. Disease-modifying antirheumatic drugs (DMARDs) are commonly used in RA treatment and classified into different categories. Nevertheless, RA treatment is based on a "trial-and-error" approach, and a substantial proportion of patients show failed therapy for each DMARD. Over the past decades, great efforts have been made to overcome treatment failure, including identification of biomarkers, exploration of the reasons for loss of efficacy, development of sequential or combinational DMARDs strategies and approval of new DMARDs. Here, we summarize these efforts, which would provide valuable insights for accurate RA clinical medication. While gratifying, researchers realize that these efforts are still far from enough to recommend specific DMARDs for individual patients. Precision medicine is an emerging medical model that proposes a highly individualized and tailored approach for disease management. In this review, we also discuss the potential of precision medicine for overcoming RA treatment failure, with the introduction of various cutting-edge technologies and big data.
类风湿关节炎(RA)是一种以炎症和骨质侵蚀为特征的自身免疫性疾病。RA的确切机制尚不清楚,但涉及各种免疫细胞因子、信号通路和效应细胞。改善病情的抗风湿药物(DMARDs)常用于 RA 的治疗,并分为不同类别。然而,RA 的治疗基于“试错”的方法,并且相当一部分患者对每种 DMARD 治疗均显示治疗失败。在过去的几十年中,人们为克服治疗失败做出了巨大努力,包括鉴定生物标志物、探索疗效丧失的原因、开发序贯或联合 DMARDs 策略以及批准新的 DMARDs。在这里,我们总结了这些努力,为 RA 的临床用药提供了有价值的见解。虽然令人欣慰,但研究人员意识到,这些努力还远远不足以推荐特定的 DMARDs 用于个别患者。精准医学是一种新兴的医疗模式,它提出了一种针对疾病管理的高度个体化和定制化的方法。在这篇综述中,我们还讨论了精准医学克服 RA 治疗失败的潜力,介绍了各种前沿技术和大数据。